An **Anti-Microsomal Antibodies** test is a diagnostic blood assay primarily used to detect and manage autoimmune thyroid disorders. These antibodies target thyroid microsomal antigens, which are now recognized as the enzyme **thyroid peroxidase (TPO)**. Consequently, this test is widely known as the **Anti-TPO antibody test**.
Elevated levels of anti-microsomal antibodies are a classic hallmark of **Hashimoto’s thyroiditis** (autoimmune hypothyroidism) and are also frequently elevated in **Graves' disease** (autoimmune hyperthyroidism). Measuring these antibodies helps clinicians confirm an autoimmune origin for thyroid dysfunction, predict the progression of subclinical hypothyroidism, and evaluate postpartum thyroiditis risks.

An **Anti-La/SSB-IgG Antibodies by EIA (Enzyme Immunoassay)** test is a targeted blood assay used to diagnose systemic autoimmune conditions. It specifically detects IgG autoantibodies directed against the **La/SSB** (Sjögren's syndrome type B) cellular antigen, which is involved in RNA processing.
This test is primarily utilized to confirm a diagnosis of **Sjögren’s syndrome**—an autoimmune disorder marked by dry eyes and dry mouth—where it often presents alongside Anti-Ro/SSA antibodies. It is also an important diagnostic marker for **Systemic Lupus Erythematosus (SLE)** and helps evaluate the risk of neonatal lupus in pregnant individuals.

An **Anti-Jo-1 Antibodies by EIA (Enzyme Immunoassay)** test is a specialized blood analysis used to diagnose autoimmune muscle diseases. It primarily screens for **Anti-Jo-1**, an autoantibody targeting the histidyl-tRNA synthetase enzyme.
This test is the primary marker for **Antisynthetase Syndrome**, a condition characterized by myositis (muscle inflammation), interstitial lung disease, arthritis, and "mechanic's hands" (rough, cracked skin on the fingertips).
Using the EIA method, the lab measures the concentration of these antibodies in the blood.

### **Anti-Hepatitis B Surface Antibodies (Anti-HBs) Test**
The **Anti-HBs (HBsAb) Titre test** is a quantitative blood assay that measures the concentration of protective antibodies against the Hepatitis B surface antigen.
* **Immunity Assessment:** It is primarily used to confirm immunity to the Hepatitis B virus (HBV), acquired either through successful vaccination or recovery from a past, resolved infection.
* **Clinical Threshold:** A titre level of **\ge 10 mIU/mL** is globally recognized as the threshold indicating active, long-term protective immunity against HBV.
* **Pre-employment & Monitoring:** This test is essential for healthcare workers, newborns of HBV-positive mothers, and immunocompromised patients to evaluate their defense status and determine the necessity of vaccine booster doses.

### **Anti-Chikungunya IgM Antibody Test**
The **Anti-Chikungunya IgM test** is a crucial serological assay for the early diagnosis of an active or recent infection with the Chikungunya virus. Immunoglobulin M (IgM) are the first antibodies produced by the immune system, typically appearing within 3 to 7 days after the onset of symptoms (primarily fever and severe joint pain).
A positive IgM result indicates a likely current or very recent infection, enabling rapid clinical intervention and public health response. The test is fundamental for differentiating Chikungunya from similar diseases like Dengue, as IgM antibodies typically remain detectable for several months before diminishing.

### **Anti-Chikungunya IgG Antibody Test**
The **Anti-Chikungunya IgG test** is a serological blood assay used to detect Immunoglobulin G (IgG) antibodies, which the immune system produces in response to the Chikungunya virus.
* **Clinical Significance:** IgG antibodies typically appear several weeks after the initial infection and can persist for months or even years, serving as a marker for past exposure or long-term immunity.
* **Diagnostic Utility:** It helps clinicians confirm previous infections, assess the prevalence of the virus in a population, and differentiate Chikungunya from other febrile illnesses like dengue or Zika.
* **Interpretation:** A positive result indicates that an individual was previously exposed to the virus, whereas a negative result suggests no past infection or that the test was performed too early.

### **Anti-Thyroid Peroxidase (Anti-TPO) Test**
The **Anti-TPO test** measures antibodies directed against thyroid peroxidase, an enzyme crucial for thyroid hormone synthesis.
* **Primary Diagnostic Tool:** It is the most sensitive laboratory marker for diagnosing autoimmune thyroid disorders, notably **Hashimoto’s thyroiditis** (the leading cause of hypothyroidism) and **Graves’ disease**.
* **Clinical Utility:** This test helps clinicians differentiate autoimmune thyroiditis from non-autoimmune goiters or general thyroid dysfunction.
* **Risk Assessment:** Identifying high anti-TPO levels is vital for evaluating the risk of postpartum thyroiditis and predicting the progression of subclinical hypothyroidism to overt thyroid disease, guiding timely treatment.

The Anti-Thyroglobulin Antibody (ATG) Test measures autoantibodies against thyroglobulin, a thyroid-produced protein. Elevated ATG levels indicate an autoimmune attack on the thyroid, often found in Hashimoto's thyroiditis and Graves' disease. The test is crucial for diagnosing autoimmune thyroiditis, distinguishing it from other thyroid conditions, and is especially significant in thyroid cancer cases. Elevated ATG in cancer follow-up can suggest recurrence or metastasis, affecting thyroglobulin (Tg) reliability as a tumor marker. Thus, ATG testing plays a key role in diagnosing autoimmune thyroid disease and monitoring thyroid cancer.

The **Anti-Thrombin III (ATIII) Antibody Test** is a specialized laboratory blood test used to investigate the specific cause of an anti-thrombin III deficiency. Anti-thrombin III is a natural anticoagulant protein that inhibits blood clotting. While functional ATIII assays measure the protein's activity, the antibody test specifically detects the presence of *acquired autoantibodies* that target and destroy ATIII.
This test is crucial for differentiating between an inherited deficiency (due to a genetic mutation) and an acquired deficiency caused by autoimmune disorders. The presence of these antibodies is strongly associated with an increased risk of severe, abnormal blood clots, such as deep vein thrombosis (DVT) or pulmonary embolism (PE). Identification helps clinicians manage thrombotic risk and determine appropriate, targeted anticoagulant therapy.

### **Anti-Sperm Antibody (ASAB)**
**Anti-Sperm Antibodies (ASAB)** are immunoglobulins that mistakenly target sperm as foreign invaders. They can be present in both male and female reproductive tracts.
* **Impact on Fertility:** ASABs bind to sperm, causing them to clump together (agglutination), which severely hinders their motility and prevents them from swimming through the female cervical mucus.
* **Fertilization Barrier:** By coating the sperm head, these antibodies can block the crucial sperm-egg interaction, preventing successful fertilization.
* **Clinical Detection:** Commonly diagnosed using Semen Analysis (Mixed Antiglobulin Reaction / Immunobead tests) or blood ELISA assays, guiding decisions for assisted reproductive treatments like IVF or ICSI.

### **Anti-Scl-70 Antibody by ELISA**
The **Anti-Scl-70 (anti-topoisomerase I) antibody ELISA test** is a blood assay used to diagnose systemic sclerosis (scleroderma).
* **Diagnostic Target:** It detects autoantibodies directed against the intracellular enzyme topoisomerase I (Scl-70).
* **Clinical Significance:** A positive result is highly specific for **diffuse cutaneous systemic sclerosis**, a severe subtype characterized by widespread skin thickening and rapid progression.
* **Risk Assessment:** Presence of these antibodies is strongly associated with an increased risk of severe internal organ involvement, particularly **interstitial lung disease (ILD)** and cardiac complications.
* **Methodology:** The Enzyme-Linked Immunosorbent Assay (ELISA) provides a rapid, quantitative measure of antibody levels to guide early therapeutic intervention.

### **Anti-Phospholipid Antibody IgM**
**Anti-phospholipid IgM** is an autoantibody produced by the immune system that mistakenly targets the body's own cell membrane lipids and associated proteins.
* **Diagnostic Role:** It serves as a primary laboratory marker for diagnosing **Antiphospholipid Syndrome (APS)**, a systemic autoimmune disorder.
* **Associated Risks:** Elevated IgM levels are strongly linked to an increased risk of abnormal blood clots (thrombosis) and recurrent pregnancy complications.
* **Testing Protocol:** Clinicians typically test IgM alongside IgG antibodies. To confirm an APS diagnosis, a positive result must remain persistent when re-tested at least **12 weeks** apart to rule out transient elevations.